Homburger advised the joint book-running managers in connection with the subsequent public offering of CRISPR Therapeutics AG
On January 4, 2018, CRISPR Therapeutics AG, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and Goldman Sachs & Co. LLC., Piper Jaffray & Co. and Barclays Capital Inc. signed an underwriting agreement with respect to the subsequent public offering of 5,000,000 shares (Underwritten Shares) at a price of USD 22.75 per share, before underwriting discounts. In addition, CRISPR Therapeutics AG has granted the underwriters an option to purchase up to 750,000 additional shares (Option Shares) which has been fully exercised by the underwriters. The gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, amounted to USD 130.8 m, including the exercise of the underwriters’ option to purchase the Option Shares. The closing of the offering with respect to the Underwritten Shares occurred on January 9, 2018, with respect to the Option Shares on January 12, 2018.
Homburger acted as legal counsel to Goldman Sachs & Co. LLC., Piper Jaffray & Co. and Barclays Capital Inc. as the joint book-running managers in the offering. The Homburger team was led by partner Frank Gerhard (Corporate / M&A) and comprised associates Céline Martin (Tax), Lorenzo Togni and Dominik Aerni (both Corporate / M&A).